Home Cart 0 Sign in  
X

[ CAS No. 75415-03-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 75415-03-1
Chemical Structure| 75415-03-1
Chemical Structure| 75415-03-1
Structure of 75415-03-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 75415-03-1 ]

Related Doc. of [ 75415-03-1 ]

Alternatived Products of [ 75415-03-1 ]

Product Details of [ 75415-03-1 ]

CAS No. :75415-03-1 MDL No. :MFCD00115151
Formula : C8H7N3 Boiling Point : -
Linear Structure Formula :- InChI Key :HKEWOTUTAYJWQJ-UHFFFAOYSA-N
M.W : 145.16 Pubchem ID :2797657
Synonyms :

Calculated chemistry of [ 75415-03-1 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 11
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 41.82
TPSA : 41.57 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.59 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.11
Log Po/w (XLOGP3) : 0.84
Log Po/w (WLOGP) : 1.47
Log Po/w (MLOGP) : 0.27
Log Po/w (SILICOS-IT) : 2.13
Consensus Log Po/w : 1.16

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -1.94
Solubility : 1.65 mg/ml ; 0.0114 mol/l
Class : Very soluble
Log S (Ali) : -1.3
Solubility : 7.35 mg/ml ; 0.0506 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.36
Solubility : 0.0638 mg/ml ; 0.00044 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.77

Safety of [ 75415-03-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 75415-03-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 75415-03-1 ]
  • Downstream synthetic route of [ 75415-03-1 ]

[ 75415-03-1 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 75415-00-8 ]
  • [ 75415-03-1 ]
YieldReaction ConditionsOperation in experiment
97.3% With hydrazine hydrate In ethanol at 60℃; for 0.5 h; Example 15
Synthesis of 2-(3-pyrazolyl)pyridine (17a)
Compound 16a (1 g, 6.2 mmol) obtained from the aforesaid process and hydrazine hydrate (2 mL) were dissolved in ethanol (3.3 mL), and reacted at 60° C. for 0.5 hour.
Then, the mixture was cooled to room temperature, and then the solvent was removed in vacuum to afford the product 17a (874.7 mg) as a faint yellow solid, with a yield of 97.3percent.
1H-NMR (400 MHz, CDCl3): δ 8.66 (d, J=4.8 Hz, 1H), 7.75 (d, J=3.6 Hz, 2H), 7.67 (d, J=2 Hz, 1H), 7.23-7.27 (m, 1H), 6.81 (d, J=2 Hz, 1H).
97.3% With hydrazine hydrate In ethanol at 60℃; for 0.5 h; Example 15
Synthesis of 2-(3-pyrazolyl)pyridine (17a)
Compound 16a (1 g, 6.2 mmol) obtained from the aforesaid process and hydrazine hydrate (2 mL) were dissolved in ethanol (3.3 mL), and reacted at 60 °C for 0.5 hour.
Then, the mixture was cooled to room temperature, and then the solvent was removed in vacuum to afford the product 17a (874.7 mg) as a faint yellow solid, with a yield of 97.3percent.
1H-NMR (400MHz, CDCl3 ): δ 8.66 (d, J = 4.8 Hz, 1H), 7.75 (d, J = 3.6 Hz, 2H), 7.67 (d, J = 2 Hz, 1H), 7.23-7.27 (m, 1H), 6.81 (d, J = 2 Hz, 1H).
Reference: [1] Patent: US2014/142144, 2014, A1, . Location in patent: Paragraph 0235; 0236; 0237
[2] Patent: EP2738169, 2014, A1, . Location in patent: Paragraph 0105; 0106; 0107
[3] Journal of the Chemical Society, Chemical Communications, 1994, # 24, p. 2751 - 2752
[4] European Journal of Inorganic Chemistry, 2007, # 26, p. 4197 - 4206
  • 2
  • [ 66521-54-8 ]
  • [ 75415-03-1 ]
YieldReaction ConditionsOperation in experiment
98% With hydrazine In ethanolHeating / reflux To a solution of 10 g (56. 7 mmol) of 3-dimethylamino-1-pyridin-2-yl- propenone in 100 mL absolute ethanol was added 1. 96 mL (62. 4 mmol, 1. 1 equiv.) of anhydrous hydrazine with stirring to give a pale yellow solution. This solution was heated to reflux and stirred overnight, then concentrated to give a tan-colored solid. The solid was then crystallized from ethyl acetate/hexane to give 8. 06 g (55. 5 mmol, 98percent) of 2-(1H-pyrazol-3-yl)-pyridine as tan-colored CRYSTALS. 1H-NMR (300 MHz, CDCI3, 8) : 11. 69 (br s, 1 H), 8. 66 (dd, J = 1 Hz, 5 Hz, 1 H), 7. 76 (d, J = 3 Hz, 1 H), 7. 74 (s, 1 H), 7. 66 (d, J = 2 Hz, 1 H), 7. 23 (t, J = 9 HZ, 1 H), 6. 81 (d, J = 3 Hz, 1 H) ; M/Z : 146 [M + H] +.
0.19 g at 50℃; for 0.166667 h; Microwave irradiation Its synthesis by conventional methods and some spectroscopic datahave been previously reported [15a,15b]. MW assisted method: A mixtureof 2-acetylpyridine (0.22 mL, 2 mmol) and DMF-dimethylacetal(0.27 mL, 2 mmol) was heated in a microwave oven for 2 h at 100 °C,and then the volatiles were removed in vacuo. The brown red solid wasmixed with hydrazine hydrate (0.2 mL, 4 mmol) and heated in a microwaveoven for 10 min at 50 °C. The volatiles were removed in vacuo,the red residue was washed with water (3×5 mL), and the ochre solidthus obtained was dried in vacuo, and recrystallized from CH2Cl2/hexane, yielding 0.19 g (65percent). IR (cm−1): 3124 m, 3058 m, 3023 m,2978 m, 2937 m, 2898 m, 2835 m, 2802 m, 2735 m, 2654 w, 2501 w,2324 w, 2165 w, 2051 w, 1981 w, 1704 w, 1590 s, 1567 m, 1536 w,1502 m, 1454 m, 1416 s, 1357 m, 1303 m, 1271 w, 1231 m, 1192 w,1144 m, 1129 w, 1088 m, 1059 m, 1048 m, 1036 w, 1000 w, 993 m,950 m, 924 w, 877 m, 843 m, 797 m, 757 vs, 704 s, 695 m, 627 m,615 m. 1H NMR (400 MHz, CDCl3) δ 11.70 (s, NH, 1H), 8.63 (dt, J=4.9and 1.2 Hz, H3′, 1H), 7.73 (dt, J=8.2 and 4.1 Hz, H6′ and H4′, 2H), 7.64(d, J=2.1 Hz, H4, 1H), 7.22 (dd, J=8.1, 4.9 Hz, H5′, 1H), 6.77 (s, H5,1H). 13C{1H} NMR (101 MHz, CDCl3) δ 206.95 (C2′), 192.18 (C3),149.43 (C3′), 136.45 (C4′ and C4), 122.80 (C5′), 120.03 (C6′), 103.32(C5).
Reference: [1] Patent: WO2004/72033, 2004, A2, . Location in patent: Page 35
[2] Journal of Medicinal Chemistry, 2015, vol. 58, # 16, p. 6389 - 6409
[3] Chemische Berichte, 1992, vol. 125, # 3, p. 701 - 710
[4] RSC Advances, 2015, vol. 5, # 43, p. 34424 - 34431
[5] Inorganic Chemistry, 2015, vol. 54, # 22, p. 10648 - 10655
[6] European Journal of Inorganic Chemistry, 2017, vol. 2017, # 3, p. 651 - 658
[7] Inorganic Chemistry, 2017, vol. 56, # 12, p. 6768 - 6771
[8] Inorganica Chimica Acta, 2019, vol. 484, p. 1 - 7
  • 3
  • [ 1122-62-9 ]
  • [ 4637-24-5 ]
  • [ 75415-03-1 ]
YieldReaction ConditionsOperation in experiment
30%
Stage #1: at 100℃; for 16 h; Reflux
Stage #2: With hydrazine hydrate In ethanol at 60℃; for 0.5 h;
A mixture of N-dimethoxymethyl-N,N-dimethylamine(10 mL) and 2-acetylpyridine (40 mL) was refluxed at 100 °C for 16 h, then concentrated by rotating evaporationto give dark brown solid. This was washed with hexane(100 mL) and diethyl ether (100 mL) to give the pure and bright yellow crystalline product. Hydrazine monohydrate (40 mL) and ethanol (15 mL) were mixed with the previously obtained solid, and the mixture was stirred at 60 °C for 30 min. After cooling, distilled water (75 mL) was added to the solution, which was kept at 0 °C for 24 h to produce a light yellow precipitate. This was recrystallized from a mixture of dichloromethane and hexane.
Reference: [1] Transition Metal Chemistry, 2018, vol. 43, # 3, p. 211 - 220
  • 4
  • [ 66521-54-8 ]
  • [ 75415-03-1 ]
Reference: [1] Synthesis, 2001, # 1, p. 55 - 62
[2] Tetrahedron Letters, 1999, vol. 40, # 26, p. 4779 - 4782
  • 5
  • [ 1122-62-9 ]
  • [ 75415-03-1 ]
Reference: [1] Synthesis, 2001, # 1, p. 55 - 62
[2] Tetrahedron Letters, 1999, vol. 40, # 26, p. 4779 - 4782
[3] Journal of the Chemical Society, Chemical Communications, 1994, # 24, p. 2751 - 2752
[4] Patent: EP1382603, 2004, A1, . Location in patent: Page 84; 85
[5] Medicinal Chemistry letters, 2012, vol. 3, # 8, p. 678 - 682,5
[6] ACS Medicinal Chemistry Letters, 2012, vol. 3, # 8, p. 678 - 682
[7] Dalton Transactions, 2014, vol. 43, # 4, p. 1524 - 1533
[8] Patent: US2014/142144, 2014, A1,
[9] Patent: EP2738169, 2014, A1,
[10] RSC Advances, 2015, vol. 5, # 43, p. 34424 - 34431
[11] Inorganic Chemistry, 2015, vol. 54, # 22, p. 10648 - 10655
[12] European Journal of Inorganic Chemistry, 2017, vol. 2017, # 3, p. 651 - 658
  • 6
  • [ 66521-54-8 ]
  • [ 75415-03-1 ]
Reference: [1] Patent: US5859215, 1999, A,
  • 7
  • [ 66521-54-8 ]
  • [ 7803-57-8 ]
  • [ 75415-03-1 ]
Reference: [1] Dalton Transactions, 2014, vol. 43, # 4, p. 1524 - 1533
  • 8
  • [ 66521-54-8 ]
  • [ 60325-13-5 ]
  • [ 75415-03-1 ]
  • [ 138785-70-3 ]
Reference: [1] Chemische Berichte, 1992, vol. 125, # 3, p. 701 - 710
Same Skeleton Products
Historical Records

Related Parent Nucleus of
[ 75415-03-1 ]

Pyrazoles

Chemical Structure| 19959-77-4

[ 19959-77-4 ]

2-(5-Methyl-1H-pyrazol-3-yl)pyridine

Similarity: 0.89

Chemical Structure| 446880-81-5

[ 446880-81-5 ]

2-Bromo-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridine

Similarity: 0.81

Chemical Structure| 149246-87-7

[ 149246-87-7 ]

5-(Pyridin-3-yl)-1H-pyrazol-3-amine

Similarity: 0.74

Chemical Structure| 2458-26-6

[ 2458-26-6 ]

3-Phenyl-1H-pyrazole

Similarity: 0.71

Chemical Structure| 149739-36-6

[ 149739-36-6 ]

3-(m-Tolyl)-1H-pyrazole

Similarity: 0.71

Pyridines

Chemical Structure| 19959-77-4

[ 19959-77-4 ]

2-(5-Methyl-1H-pyrazol-3-yl)pyridine

Similarity: 0.89

Chemical Structure| 446880-81-5

[ 446880-81-5 ]

2-Bromo-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridine

Similarity: 0.81

Chemical Structure| 149246-87-7

[ 149246-87-7 ]

5-(Pyridin-3-yl)-1H-pyrazol-3-amine

Similarity: 0.74

Chemical Structure| 74173-48-1

[ 74173-48-1 ]

4-Methyl-4'-vinyl-2,2'-bipyridine

Similarity: 0.72

Chemical Structure| 56100-20-0

[ 56100-20-0 ]

5-Methyl-2,2'-bipyridine

Similarity: 0.70